A recent study found that only one-third of patients with sickle cell disease received guideline-adherent pain treatment within the first hour at emergency departments. The study analyzed data from over 398,000 visits and found disparities in treatment based on age, sex, and insurance status.
Researchers found that measurable residual disease (MRD) is strongly associated with long-term outcomes in AML patients, providing a reliable indicator of treatment response. MRD testing may help refine how physicians assess treatment efficacy and personalize post-remission care.
Researchers have discovered that a chemotherapy drug can improve outcomes in stem cell transplants when donors and recipients are unrelated and have significant genetic differences. The study showed comparable survival rates and lower risks of complications among patients receiving transplants with more or less extensive genetic mismat...
Black patients with acute myeloid leukemia are diagnosed at younger ages and have worse outcomes compared to white patients, according to a study analyzing data from 10 clinical trials over 34 years. The study found that Black patients had a higher risk of dying from AML and any cause, even when treated with similar mutations.
A study of over 1,000 patients found that hematopoietic cell transplantation eliminated sickle cell disease symptoms in most patients, with a 90% seven-year survival rate. Late effects were mostly liver and lung issues, but the procedure's benefits outweighed risks for many patients.
Fred Hutch experts will present CAR-T access expansion, new AML treatment strategies, and the impact of climate on cancer. Experts discuss optimizing maintenance therapy using MRD-directed approaches for high-risk AML patients and evaluating the safety & efficacy of combining PIVEK with FLAG-IDA for adults with untreated AML.
Researchers from Mass General Brigham Cancer Institute present promising new treatment options for acute myeloid leukemia, autoimmune bleeding disorders, and multiple myeloma. The studies show improved event-free survival, higher overall response rates, and better quality of life for patients treated with novel therapies.
The updated 2025 American Society of Hematology guidelines recommend that most older adults with acute myeloid leukemia (AML) receive treatment, including gentler chemotherapy regimens and targeted therapies. The guidelines aim to provide more personalized and effective care for this patient population.
Researchers from Penn Medicine will present data on latest advances in blood cancer and classical hematology research at the 67th American Society of Hematology Annual Meeting. The presentation includes updates on preclinical, clinical, and population-based research, as well as a multicenter Phase II study and a randomized phase III tr...
Researchers from the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center will present their work on various hematological conditions at ASH 2025. These posters highlight recent findings in fields such as von Willebrand disease, multiple myeloma, and acute myeloid leukemia.
City of Hope experts will highlight advances in blood cancer research, cellular therapies, and precision medicine at the 2025 American Society of Hematology Annual Meeting and Exposition. The meeting will feature over 105 sessions covering topics such as CAR T cell therapy, transplant innovations, and precision medicine.
Multiple Sylvester physicians presented their research on various hematological cancers, including lymphoma and myeloma. The studies showcased promising results for treatments such as CAR-T therapy and immunotherapy combinations.
A biomarker study found that low placental growth factor (PlGF) levels can predict early-onset preeclampsia in pregnant women with sickle cell disease. The researchers identified a PlGF threshold of 87 pg/mL at 20-24 weeks as effective for predicting early-onset preeclampsia and late-onset preeclampsia, respectively.
Mikkael Sekeres has been elected to the Executive Committee of the American Society of Hematology (ASH), a four-year term starting after the 2025 ASH Annual Meeting. He will help strengthen the organization's mission in shaping the future of hematology.
A study published in Blood Advances found that individuals with sickle cell disease who were triaged appropriately received their first dose of pain medication within 60 minutes, while those triaged at lesser severity levels waited nearly three times as long. The researchers analyzed the impact of emergency severity index (ESI) assignm...
A new study assesses ChatGPT 3.5's performance on hematology-oncology tasks, revealing its strengths and limitations in providing accurate information for patients. The study highlights the importance of physician oversight when using AI-generated medical information.
Treatment with exagamglogene autotemcel (exa-cel) leads to clinically meaningful improvements in overall quality of life for patients with severe sickle cell disease and transfusion-dependent beta thalassemia. Patients experience substantial improvements in physical, social, functional, and emotional well-being, with sustained benefits...
The study found that only 16% of newly diagnosed patients with MDS on Medicare received HMAs during the period analyzed, with women and non-white patients being less likely to start treatment. The analysis suggests that making changes with existing therapies and administration can have a huge impact on improving outcomes in high-risk MDS.
Physicians from Ruhr-University Bochum used CAR T-cell therapy to treat two patients with chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disease causing paralysis and loss of sensation. The treatment showed rapid and long-lasting effects, with significant improvements in symptoms and functional abilities.
Nancy A. Speck has been recognized for her groundbreaking research on hematopoiesis and leukemogenesis, with a focus on the transcription factor complex core binding factor. Her work has provided critical knowledge to understand how certain blood cancers develop, leading to significant insights in embryonic blood cell formation.
Patients with metastatic colorectal cancer treated with biweekly TAS-102 showed similar treatment effectiveness while experiencing reduced toxicity and lower rates of myelosuppression compared to standard dosing. This alternative schedule may be particularly useful for older patients or those with chemotherapy-related toxicities.
A new study from Fox Chase Cancer Center researchers found that implementing a Best Practice Advisory in the electronic medical record system increased oncofertility referrals by 450%. This led to 14 successful fertility preservation cases within six months, compared to just 22 in the previous five years.
A new algorithm standardizes care for children with sickle cell disease who present to the ED with a fever, reducing hospitalizations by 10% without increasing readmissions. The algorithm uses predefined risk factors to determine treatment, making it safer and more efficient.
The new guidelines aim to improve health outcomes by providing evidence-based recommendations for managing VTE in children. Direct oral anticoagulants are now recommended as a first-line treatment option in many cases.
A real-world study of 2,147 children with sickle cell disease found that hydroxyurea reduced emergency department visits by 0.36 fewer times per patient-year and hospital stays by 0.84 fewer days per patient-year. Improvements in hemoglobin concentration were seen only in patients who consistently took the medication.
A new machine learning model improves risk assessment for patients with myelofibrosis seeking a transplant, identifying high-risk patients with a 40% chance of dying within a year. The open-access model provides a practical tool for clinicians to enhance shared decision-making with their patients.
Kimberly Stegmaier appointed as Chair of Pediatric Oncology at Dana-Farber Cancer Institute and Associate Chief of Division of Hematology/Oncology at Boston Children's Hospital. She will focus on acute leukemias and pediatric solid tumors, pioneering genomic approaches to identify new therapies for childhood cancer.
A systematic literature review found no evidence to support a link between physical exertion without rhabdomyolysis or heat injury and sudden death in individuals with sickle cell trait. The review's findings refute the attribution of sudden death to SCT, a condition affecting over 100 million people worldwide.
Researchers found that inhibiting protein RSK1 reduces inflammation and stops progression of blood cancers like myeloproliferative neoplasms and acute myeloid leukemia. The RSK1 inhibitor is already in clinical trials for breast cancer and shows promise as a treatment for blood cancers.
A recent study by Michigan Medicine found that reducing the dose of popular blood thinners like Xarelto and Eliquis can lower the risk of future bleeding events. The research team analyzed nearly 1,000 cases of patients who took these medications to prevent recurrent clots after having a blood clot.
Researchers analyzed data from 11,797 adults with advanced solid cancers and found no difference in mortality rates during the shortage period. Prescription rates for cisplatin and carboplatin fell less than three percent overall, with alternative therapies helping mitigate the crisis.
Researchers discovered a gene variant in high-altitude Andean populations that can help predict the severity of certain types of blood cancer. The NFKB1 gene variant is associated with lower inflammation levels and better treatment responses in patients with myeloproliferative neoplasms.
Stephen D. Nimer, MD, has been awarded the American Society of Hematology's (ASH) Mentor Award for 2024 for his impact on over 100 hematology trainees who have gone on to have thriving careers. He is recognized for creating a collaborative environment that drives scientific discovery and quality patient care.
A new treatment shows promise for people with high-risk smoldering multiple myeloma, delaying cancer progression and improving overall survival. Daratumumab significantly reduces risk of progression to active disease and improves patient outcomes.
Researchers observed a 100% response rate on Phase Ib trial for patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis. Early intervention with ELA026 may provide meaningful clinical benefits for patients with few options.
Dr. Christopher Seet has received a $2.9 million R37 MERIT Award from the National Cancer Institute to develop innovative T cell therapies for cancer. The grant will support research into iPSC-derived T cells, which can be engineered for enhanced tumor-fighting capabilities.
Researchers are working to develop a curative treatment for multiple myeloma by combining treatments, overcoming resistance, and tailoring therapy to individual patients. The study found promising results using bispecific antibodies in combination with other treatments.
Dana-Farber Cancer Institute researchers present promising results from two studies on systemic mastocytosis: a novel drug, bezuclastinib, shows early efficacy in treating advanced SM, while a new predictive tool distinguishes between life-threatening and less aggressive forms of the disease with high accuracy
The study presents strong overall responses with a triplet regimen including a novel menin inhibitor, achieving an 82% overall response rate in relapsed or refractory acute myeloid leukemia patients. The combination also demonstrated manageable side effects and significant clinical benefits, providing patients with improved treatment o...
A phase 3 trial found that combining a second-generation BTK inhibitor, acalabrutinib, with a BCL-2 inhibitor, venetoclax, resulted in high progression-free survival rates and low toxicity. The treatment showed promise in treating chronic lymphocytic leukemia (CLL) patients.
Two clinical trials testing loncastuximab tesirine showed promising results in patients with high-risk forms of follicular lymphoma and marginal zone lymphoma. The treatment achieved impressive response rates, including a 70% complete response rate for marginal zone lymphoma and an overall response rate of 97% for follicular lymphoma.
Researchers found that a ketogenic diet's beta-hydroxybutyrate (BHB) improves tumor control and survival in mice with diffuse-large B-cell lymphoma. A BHB supplement also boosts CAR T cell expansion and activation in laboratory models of human cancer.
Researchers at Dana-Farber Cancer Institute have led three studies that provide new insights into treating acute myelogenous leukemia (AML) in various high-risk subtypes. The findings reveal that CPX-351 has a survival benefit for patients with AML-MR mutations, but may not be effective for those with TP53 or DDX41 mutations.
Researchers at MD Anderson Cancer Center presented findings on novel treatments for MDS, including luspatercept, which significantly reduced the need for blood transfusions in lower-risk patients. Additionally, a triplet therapy regimen improved survival in older adults with FLT3-mutated AML.
Researchers at Fred Hutchinson Cancer Center are addressing socioeconomic barriers to access to life-saving transplants for blood disorders. New leukemia treatment regimens have shown promise in clinical trials, while a prediction model highlights improved survivorship and quality of life outcomes for older patients after transplant.
Mass General Brigham researchers presented research discoveries and outcomes from clinical trials on immune thrombocytopenia, early phase therapies, myeloproliferative syndromes, advances in treatment of lymphomas and leukemias. A novel prognostic score for relapsed/refractory mature T-cell and NK-cell lymphomas was also developed.
The ASH Minority Recruitment Initiative shows lower attrition rates for participants in graduate and medical programs, leading to more career pursuits in hematology. Participants also exhibit high levels of engagement with the American Society of Hematology beyond their program participation.
Sylvester researchers will present over 130 studies at ASH 2024, addressing disparities in gastric cancer. Frank J. Penedo's research highlights worse outcomes for patients with unmet supportive needs, while Shria Kumar's work seeks answers for disparities in gastric cancer among specific minorities.
Researchers from the Sylvester Comprehensive Cancer Center presented their findings on the association between smoking intensity, genetic mutations, and disease progression in myelodysplastic syndromes. Dr. Stephen D. Nimer received the 2024 ASH Mentor Award for his impact on hematology trainees.
More than 70 hematology researchers from the University of Miami Miller School of Medicine will showcase their work at the 66th ASH Annual Meeting & Exposition. Researchers from Sylvester Comprehensive Cancer Center are authors or co-authors on a significant number of posters presented during the event.
The ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present several abstracts at the 66th American Society of Hematology Meeting & Exposition. Promising results from a phase 2 study in acute myeloid leukemia and new data from the practice-changing E1910 phase 3 trial show improved outcomes for patients with B-cell acute lymphobla...
A new study found that preschool-aged children with sickle cell disease who live in food deserts and have limited access to transportation are at greater risk for acute complications and hospitalizations. Living in a household located more than one mile from a supermarket was associated with a 44% increase in hospitalizations.
A single-dose gene therapy has been shown to significantly reduce bleeding episodes in adults with hemophilia B, with an average reduction of 71% compared to standard treatment. The therapy, which enables the liver to produce clotting factor IX, has been FDA-approved for use in patients with this genetic disorder.
Researchers have found a potential compound that pairs well with an IRAK4 inhibitor to kill AML cells by reducing c-Myc levels, a protein also driving cancer growth. The three-year LLS grant will allow further research into the effects of IRAK4 targeting on c-Myc.
A year-long pilot program found that external mentorship increased confidence, furthered career development, and facilitated networking opportunities for trainees in classical hematology. The program paired hematology/oncology fellows with mentors outside their institutions to meet virtually each month.
Researchers identified a population of stem-like cells that initiates and maintains Group 3 medulloblastoma (Gr3-MB) in the developing brain. Eliminating these cells led to tumor shrinkage in preclinical models, suggesting a novel approach for treating children with Gr3-MB.
A Cleveland Clinic-led team of scientists discovered that protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment. The interaction between VISTA and a newly discovered inhibitory receptor LRIG1 suppresses T cell replication, survival, and function.
A nationwide training program aims to equip clinicians with digital tools for targeted fatigue, insomnia, pain, depression, and anxiety in cancer patients. The project will train 600 clinicians in technology-augmented care.
A Cleveland Clinic study uses reinforcement learning to design antibiotic regimens that minimize resistance and maximize susceptibility. The AI model predicts the most efficient treatment plans for multiple strains of E. coli, informing hospital-wide infection management.
Researchers found that discontinuing specialist follow-up care for patients with slow-growing CLL had no negative impact on survival, hospital visits or infections. Most patients who ended follow-up developed minor infections treated with antibiotics.